Investigation of in Vivo Endogenous and/or Exogenous Production of Phenolic Metabolites Using (un)Targeted Metabolomics

NCT ID: NCT06028659

Last Updated: 2025-04-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-10-25

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Plant (poly)phenols is what we call a large number of substances that are produced by plants as secondary plant metabolites, which means substances that are not used for their growth and development but are necessary for them to survive. (Poly)phenols are divided in two major groups, flavonoids, and non-flavonoids, and each group contains a varied set of subgroups and substances. They are widely spread in fruit and vegetables that are part of the human diet, and, in general, studies have attributed many biological effects to the ingestion of (poly)phenols, especially in the prevention of non-communicable diseases. For this reason, research aims to understand their role in the health benefits of a diet that is rich in fruits and vegetables. When ingested, (poly)phenols are digested by both the human organism and the gut microbiota and are broken down into several smaller substances (catabolites) that are called low-molecular weight (poly)phenols (LMWP). Most of the absorbed (poly)phenols that reach our bloodstream and organs are LMWP.

For the proposed study, 30 healthy adults will be recruited and, if considered able to participate, will follow a standardized diet that is restricted in (poly)phenol intake and will be randomly divided into two groups: one will receive a known source of (poly)phenols (coffee) and the other will receive water, keeping the restriction of (poly)phenol from the diet. The duration of one phase is 4 days + 12 hours, during which urine, feces, and saliva will be collected. Then, after a 2-week-interval, subjects will repeat the experiment, except that this time the group who had coffee will have water, and vice versa. Again, urine and feces will be collected. The objective of the study is to identify and quantify LMWP mainly in urine, but also in feces, and try to understand how much was produced when there was no (poly)phenols in the diet compared with when there was ingestion of coffee (poly)phenols. The production of LMWP without coffee could be because of their production from other sources, like the metabolism of amino acids, proteins, and catecholamines (i.e. dopamine). The composition of the gut microbiota and relevant genetic information can alter the metabolism of (poly)phenols and will be considered in the analyses. Knowing how much of LMWP actually comes from the diet is important to understand the relevance and health benefits of these molecules.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will consist of a randomized cross-over trial and each arm will last 5 days. A total of thirty (30) healthy volunteers will be recruited for the study in Parma (PR), using announcements placed in the university, hospital, and public places. To allocate subjects to each arm, a list will be generated using a randomized block design by using Random Number Generator Pro (Segobit Software). This list will be blind for the PI and volunteers, as it will be made by a colleague not involved in the subjects' enrolment and using a numbered sequence in sealed, opaque envelopes.

Volunteers freely accepting to participate to the study will be asked for their written informed consent. Information to the volunteers will be provided before and separately from the consent form. These information sheets and the informed consent forms have been prepared according to the Oviedo Convention and consider the guide of the local Ethics Committee. After obtaining their written informed consent, volunteers will undergo a screening visit to determine eligibility and collect personal data.

Privacy of the volunteers will be assured through pseudoanonymization by the attribution of a personal alphanumeric code. Recruited volunteers will also sign an authorisation to the use of personal information and retrieved data.

After recruitment, subjects will attend a first visit, when personal data will be collected, and body composition and anthropometry parameters measured. Then, they will receive the foods, supplements, and materials necessary to follow the study. The recruited subjects will be requested to follow a low-(poly)phenol diet, which will be the same for all the volunteers and maintained for the whole period of the intervention study. The foods, preparation mode, and times for eating the meals will be provided by the sponsor. The diet will be personalised to approximate the necessary calories based on the measured basal metabolic rate, multiplied by the physical activity level set at 1.45, and there will be quantitative variations on the low-(poly)phenol diet based on the daily energy requirement: 1500 kcal/day, 1750 kcal/day, 2000 kcal/day, 2250 kcal/day, 2500 kcal/day, 2750 kcal/day, or 3000 kcal/day, all with nutritionally balanced amounts of protein, fat, and carbohydrates. In addition, participants will be requested to restrict physical exercise during the study duration.

Subjects will be asked to collect urine produced during the 60h prior the intervention, starting from the evening prior the first day of diet (from 21.00 of the night prior the first day of diet) and every 12 hours (60-48h, 48-36h, 36-24h, 24-12h, 12-0h), and to complete the food diary to check for compliance to the diet. Subjects are asked to bring collected urine to the the Human Nutrition Unit of the Food and Drug Department of the University of Parma.

On the morning of the third day of diet, subjects will be requested to arrive at Parma University in fasting conditions. Prior to receiving the intervention, fasting spot urine and saliva samples will be collected. Then, sugared-decaffeinated-coffee (3 doses of 50 mL each and 5g of sugar) or sugared-water (150 mL of water and 5g of sugar) will be provided according to randomization of the arms, along with a standardized breakfast consisting of a (poly)phenol-free, nutritionally balanced solid meal and water (ad libitum).

After breakfast, subjects will be asked to autonomously collect urine for the next 48h at specified timepoints (0 - 3h; 3 - 6h; 6 - 9h; 9 - 12h; 12 - 24h; 24 - 36h; and 36 - 48h), following the same personalized diet. Lastly, subjects will autonomously collect a fecal sample within 6 to 48h after the intervention.

On the morning of the last day, after the last urine collection, subjects will bring collected urine and fecal samples and the 5-day food diary to the Human Nutrition Unit of the Food and Drug Department of the University of Parma.

After the first arm, subjects will resume their habitual lifestyles for 2 consecutive weeks, subsequently, they will attend another visit, when all the anthropometric evaluations carried out during the first visit will be repeated and another kit with foods and information for the personalized diet will be given. With the study being a cross-over design, the protocol followed will be the same as the one described above (except for saliva sampling, which will only be performed once). Coming the third day of diet, subjects who ingested coffee in the prior arm of the study will ingest water, and vice-versa.

For this study, the sample size was estimated considering the mean concentration of coffee-derived (poly)phenols and their metabolites in urine as the primary outcome and the available literature on similar approaches and studies of the area. The number of 30 volunteers was established considering the accepted parameters for clinical trials (power set at 0.8 and α set at 0.05) possible dropouts (15% drop-out rate), and exclusion of volunteers to maintain the sample power for statistical analysis. Before any comparison is performed, the normality of each variable will be evaluated to choose the most appropriate statistical test. If metabolite data are normally distributed, data will be expressed as mean ± standard deviation and analysed using repeated measures t-test or ANOVA with post-hoc comparisons. If data are not normally distributed, they will be reported as median and Interquartile Range and the Friedman test with post hoc pairwise comparisons will be performed. P-value \< 0.05 will be regarded as statistically significant.

Unsupervised and supervised multivariate analysis will be used to identify and characterize the different urinary metabotypes, following the procedures developed by our research group for targeted metabolomics analysis of phenolic metabolites or when using untargeted metabolomics data. We will be using different clustering approaches to better explore the existing variability. This will serve to establish the number of clusters (i.e., phenolic metabotypes), the number of participants forming each cluster and the similarities among possible metabotypes.

The relationship between patterns of LMWP and their putative determinants (age, sex, ethnicity, lifestyle, anthropometrics, body composition, genotype, and gut microbiome) will be explored using correlation tests and multivariate analyses. P-value \< 0.05 will be regarded as statistically significant. Statistics will be carried out by the specialized staff of the Human Nutrition Unit, under the supervision of the PI, and in collaboration with the University teams in charge of microbial profiling and genotyping.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Individual Variability in (Poly)Phenol Metabolism

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

SCREENING

Blinding Strategy

TRIPLE

Participants Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Coffee

In this arm, volunteers will receive, once, 3 decaffeinated coffees (150 mL total) with sugar as a known source of (poly)phenols.

Group Type EXPERIMENTAL

Coffee

Intervention Type OTHER

Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

Control

In this arm, volunteers will receive, once, 150 mL of sugared water as control.

Group Type OTHER

Water

Intervention Type OTHER

150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coffee

Decaffeinated coffee with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

Intervention Type OTHER

Water

150 mL of hot water with 1 pack (5g) of sugar from commercially available brands prepared with commercially available domestic coffee machines.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Apparently healthy adults,
* Age 20-40 years old,
* Body mass index (BMI) between 18-28,
* Regular coffee consumers (at least 1 cup a day).

Exclusion Criteria

* Clinical diagnosis of metabolic diseases,
* Clinical diagnosis of cardiovascular diseases,
* Clinical diagnosis of renal diseases,
* Clinical diagnosis of digestive diseases,
* Immunodeficiency
* Autoimmune diseases (other than well-compensated hypothyroidism),
* Mental disorders
* Regular use of medication (except birth-control pills and hormone replacement therapies),
* Use of antibiotics in the last month prior to enrollment,
* Food allergies or intolerances,
* Pregnancy
* Lactation
Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Parma

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Pedro M. Mena Parreño

Principal Investigator

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Pedro M Mena Parreño, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Parma

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Parma - Plesso Biotecnologico Integrato

Parma, PR, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Pedro M Mena Parreño, PhD

Role: CONTACT

+393288087332

Letizia Bresciani, PhD

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Pedro M Mena Parreño, PhD

Role: primary

+39 0521 903970

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

340/2023/SPER/UNIPR

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Polyphenols and Endothelial Function
NCT00619749 TERMINATED PHASE3
Interindividual Variation in Response to Green Coffee
NCT06204445 ACTIVE_NOT_RECRUITING NA